June 9 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.N VRX.TO is considering the sale of Egyptian drugmaker
Amoun Pharmaceutical Co to accelerate its debt-reduction plan,
Bloomberg reported, citing people with knowledge of the matter.
Valeant is working with Goldman Sachs Group (NYSE:GS) on the sale,
which is at a preliminary stage, according to the report. It is
also weighing a sale of some of its Latin American operations,
Bloomberg reported. (http://bloom.bg/1U9mDh3)
Valeant bought Amoun for about $800 million last year.
Valeant, which earlier in the week reported
lower-than-expected first quarter profit, could not be
immediately be reached for comment.
The Canadian company has said that it is aiming to lower its
almost $30 billion debt.